BTIG on Immunitybio Inc (IBRX): FDA warning letter issue 'likely resolvable,' selloff a buying oppty
Tweet Send to a Friend
BTIG analyst Jeet Mukherjee reiterated a Buy rating and $13.00 price target on Immunitybio Inc (NASDAQ: IBRX)The analyst commented, "IBRX ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
